Presentation of dr. Marcel van der Sluis, Manager BD Drug Development Cluster at the Workshop 'From Innovation to Commercialisation' during the Dutch Life Sciences & Health Conference 2010
Pfizer Canada is exploring public-private partnerships and open innovation models to address gaps in drug innovation. These models include pre-competitive research partnerships and consortia involving multiple companies, universities, and research institutions. They aim to leverage diverse scientific capabilities and resources to make progress on understanding disease biology and developing new treatments. By sharing knowledge and resources in a pre-competitive space, these partnerships seek to accelerate innovation for the benefit of patients while also engaging industry, academia and government.
The document discusses a manufacturing platform for producing therapeutics in tobacco plants. It summarizes meetings with experts on commercializing biotech platforms and understanding customers. Experts advised validating the platform by producing hard-to-make proteins, focusing on technical/manufacturing customers, and understanding regulatory issues. Customers cited interest in cost-effective production and combination vaccines. Next steps include further challenging the value proposition and better understanding commercialization and decision-making processes through additional expert meetings.
This document discusses Discovery Driven Planning (DDP), a methodology for evaluating, planning, and managing uncertain growth projects. It describes the five key disciplines of DDP: 1) framing a worthwhile challenge, 2) recognizing competitive market metrics, 3) identifying and documenting assumptions, 4) outlining major deliverables, and 5) identifying major checkpoints to test assumptions. DDP uses staged investment and assumption testing to minimize risk and control downside potential while maximizing upside opportunities for projects with uncertainty.
This document discusses Actelion Pharmaceuticals' desire to partner its S1P1 agonist program. It provides background on Actelion and the program. It then discusses trends in pharmaceutical partnering over the last 30 years, with alliances rising to displace other forms of partnerships. The document goes on to describe a stage-gate approach to identify potential partner candidates. It applies scoring tools and risk analysis to 6 firms to identify the most appropriate partners for due diligence.
The document discusses Thermo Scientific's leadership in serving science through analytical instruments, equipment, reagents, software and services. It highlights the company's size and scale, unmatched capabilities, portfolio of leading brands, and mission to make the world healthier, cleaner and safer. Key strengths include global industry leadership, ability to continuously invest in growth opportunities through R&D, and an excellent track record of financial performance. New products are presented for applications such as sample preparation, analysis, and data interpretation.
UL Product Mindset Industry Report Building MaterialsUL
This report is a complement to a global study, Navigating the Product Mindset, that features marketplace trends, statistical data, differing stakeholders, varied geographies, diverse industries and a technical panel of UL experts. This report presents the key findings related to the building materials industry. It is based on 2,430 quantitative interviews with manufacturers and consumers across a range of significant export and import markets — China, Germany, India and the United States.
Navigating the Product Mindset and its additional industry reports seek to better understand market forces; drivers of decisions; findings related to safety, performance, sustainability and innovation; and the motivations behind these views.
This paper explores biopharma industry challenges in product development and innovation, defines PLM for the industry and provides guidance on how to get started on the PLM journey.
BioProsperity is a life sciences consulting firm founded in 2009 that specializes in market research, business analysis, and technology transfer. The firm offers services including deal advisory, strategic consulting, and technology commercialization to clients in industries like healthcare, pharma, food tech, and more. BioProsperity aims to combine scientific expertise with business acumen to provide the best advice. The firm carries experience across all stages of product and company development. Current projects include assisting partners in commercialization strategies, due diligence assessments, and developing exploitation plans for new technologies.
Pfizer Canada is exploring public-private partnerships and open innovation models to address gaps in drug innovation. These models include pre-competitive research partnerships and consortia involving multiple companies, universities, and research institutions. They aim to leverage diverse scientific capabilities and resources to make progress on understanding disease biology and developing new treatments. By sharing knowledge and resources in a pre-competitive space, these partnerships seek to accelerate innovation for the benefit of patients while also engaging industry, academia and government.
The document discusses a manufacturing platform for producing therapeutics in tobacco plants. It summarizes meetings with experts on commercializing biotech platforms and understanding customers. Experts advised validating the platform by producing hard-to-make proteins, focusing on technical/manufacturing customers, and understanding regulatory issues. Customers cited interest in cost-effective production and combination vaccines. Next steps include further challenging the value proposition and better understanding commercialization and decision-making processes through additional expert meetings.
This document discusses Discovery Driven Planning (DDP), a methodology for evaluating, planning, and managing uncertain growth projects. It describes the five key disciplines of DDP: 1) framing a worthwhile challenge, 2) recognizing competitive market metrics, 3) identifying and documenting assumptions, 4) outlining major deliverables, and 5) identifying major checkpoints to test assumptions. DDP uses staged investment and assumption testing to minimize risk and control downside potential while maximizing upside opportunities for projects with uncertainty.
This document discusses Actelion Pharmaceuticals' desire to partner its S1P1 agonist program. It provides background on Actelion and the program. It then discusses trends in pharmaceutical partnering over the last 30 years, with alliances rising to displace other forms of partnerships. The document goes on to describe a stage-gate approach to identify potential partner candidates. It applies scoring tools and risk analysis to 6 firms to identify the most appropriate partners for due diligence.
The document discusses Thermo Scientific's leadership in serving science through analytical instruments, equipment, reagents, software and services. It highlights the company's size and scale, unmatched capabilities, portfolio of leading brands, and mission to make the world healthier, cleaner and safer. Key strengths include global industry leadership, ability to continuously invest in growth opportunities through R&D, and an excellent track record of financial performance. New products are presented for applications such as sample preparation, analysis, and data interpretation.
UL Product Mindset Industry Report Building MaterialsUL
This report is a complement to a global study, Navigating the Product Mindset, that features marketplace trends, statistical data, differing stakeholders, varied geographies, diverse industries and a technical panel of UL experts. This report presents the key findings related to the building materials industry. It is based on 2,430 quantitative interviews with manufacturers and consumers across a range of significant export and import markets — China, Germany, India and the United States.
Navigating the Product Mindset and its additional industry reports seek to better understand market forces; drivers of decisions; findings related to safety, performance, sustainability and innovation; and the motivations behind these views.
This paper explores biopharma industry challenges in product development and innovation, defines PLM for the industry and provides guidance on how to get started on the PLM journey.
BioProsperity is a life sciences consulting firm founded in 2009 that specializes in market research, business analysis, and technology transfer. The firm offers services including deal advisory, strategic consulting, and technology commercialization to clients in industries like healthcare, pharma, food tech, and more. BioProsperity aims to combine scientific expertise with business acumen to provide the best advice. The firm carries experience across all stages of product and company development. Current projects include assisting partners in commercialization strategies, due diligence assessments, and developing exploitation plans for new technologies.
UL Product Mindset Industry Report Household ChemicalsUL
The document summarizes key findings from a study on the household chemicals industry. It finds that:
1) Manufacturers are confident in their product safety and innovation but less so in sustainability. Rising costs are their biggest supply chain challenge.
2) Product reliability impacts manufacturers' ability to compete currently, while innovation will be most important in the future.
3) Manufacturers see themselves as responsible for product safety and communicating it to consumers.
4) Consumers find product safety and performance most important when evaluating household chemicals and have concerns about long term exposure and skin irritation.
5) It is difficult for consumers to find product safety information about household chemicals.
This document summarizes an upcoming conference on pre-filled syringes in Europe. The two-day conference will feature presentations and discussions on pre-filled syringe formulations, filling and finishing processes, primary and secondary packaging developments, regulatory compliance, and patient safety approaches. It will also include two post-conference workshops on self-injection devices and safety issues within pre-filled syringes. Key industry leaders and experts will speak on topics such as biologics formulations, extractables and leachables, facility design strategies, and regulatory trends. The conference aims to explore challenges and solutions for pre-filled syringe development and commercialization.
This document provides an agenda for the "2nd Prefilled Syringes Americas" conference taking place from April 5-7, 2011 in the USA. The conference will discuss trends in pre-filled syringes including new materials, components, and processes. Key topics include plastic syringe systems, drug delivery devices, technological developments, and advanced formulations for biologics. Speakers will represent companies like Bristol-Myers Squibb, Gerresheimer, West Pharmaceutical, and Arecor. The event aims to explore industry requirements and the latest innovations in pre-filled syringe product development.
7th Cold Chain Distribution for PharmaceuticalsAbby Lombardi
This document provides information about the 7th Annual Cold Chain Distribution for Pharmaceuticals conference taking place from September 21-24, 2009 in Philadelphia, Pennsylvania. The conference will focus on partnerships, transportation processes, risk mitigation and temperature-controlled shipment of pharmaceutical products and supplies. Topics will include re-evaluating transportation and logistics strategies, ensuring regulatory compliance, establishing qualified shipping lanes and processes, and implementing effective "last mile" logistics. The conference will feature speakers from various pharmaceutical and logistics companies and government agencies. Pre-conference discussion forums and conference tracks will address issues such as cold chain program management, new refrigeration technologies, biological materials and clinical supplies shipping, and clinical logistics.
Will Biosimilars Be A Driver For InnovationAjaz Hussain
The Biosimilar debate touches upon several important reasons for innovation failure in a regulated environment – successful, scientific, resolution will be important for the entire sector.
The document discusses using a tobacco-based manufacturing platform for rapidly and cost-effectively producing vaccines and therapeutics. It outlines the business model, which involves licensing the technology to larger biotech companies, and describes initial customer feedback indicating the flu vaccine market may be difficult to enter but the therapeutics market, such as for alpha-1 antitrypsin, could be more promising. Prototyping efforts involve further characterizing alpha-1 antitrypsin production in tobacco plants.
This document discusses brand development and new product development (NPD). It begins with an introduction of the presenter, David G. Elliott, including his background in health and beauty marketing. The document then discusses how NPD involves both art and science. It provides examples of how to strategically develop brands through understanding consumer and shopper research, motivations, and retail needs. The summary emphasizes that successful NPD requires a strategic approach considering both the artistic and scientific elements of creating new products that meet consumer and retailer expectations.
The CDDI approach provides drug development services through a virtual asset development model using an external team of experienced professionals. This allows clients to outsource drug development functions and access dedicated experts in a flexible manner. By using CDDI's virtual teams, clients can reduce costs and infrastructure while expediting development timelines.
This report is a complement to a global study, Navigating the Product Mindset, that features marketplace trends, statistical data, differing stakeholders, varied geographies, diverse industries and a technical panel of UL experts. This report presents the key findings related to the food industry. It is based on 2,430 quantitative interviews with manufacturers and consumers across a range of significant export and import markets — China, Germany, India and the United States.
Navigating the Product Mindset and its additional industry reports seek to better understand market forces; drivers of decisions; findings related to safety, performance, sustainability and innovation; and the motivations behind these views.
The MIT Consortium on Adventitious Agent Contamination in Biomanufacturing aims to identify best practices for preventing contamination of biomanufacturing processes. The Consortium will provide a collaborative environment for member companies to share experiences and develop solutions. Initial projects include collecting and analyzing industry virus contamination data in a confidential manner to determine risk factors and mitigation strategies. The goal is to advance practices for ensuring product safety and quality.
This report is a complement to a global study, Navigating the Product Mindset, that features marketplace trends, statistical data, differing stakeholders, varied geographies, diverse industries and a technical panel of UL experts. This report presents the key findings related to the high-tech industry. It is based on 2,430 quantitative interviews with manufacturers and consumers across a range of significant export and import markets — China, Germany, India and the United States.
Navigating the Product Mindset and its additional industry reports seek to better understand market forces; drivers of decisions; findings related to safety, performance, sustainability and innovation; and the motivations behind these views.
This document presents a generic modular framework for implementing innovation and commercialization-oriented curricula through scenario-based and experiential learning. The framework is adaptable and scalable, covering topics like opportunity recognition, intellectual property, finance, and business strategy. Assessment includes feasibility reports, presentations, research tasks, and reflective logs.
The School of Bioscience applies this framework through student "company teams" that invent marketable biotech products addressing global issues. External speakers provide discipline-relevant content, and weekly plans guide students through a scenario culminating in a feasibility report and company pitch. Feedback indicates the innovative methodology develops students' commercial awareness and employability skills.
Slides from the CEDIM Innovation Series presentation. Includes a new business model framework, the business model as strategy cube and a design thinking oriented approach to business model innovation. @cedim
This document discusses business transformation and innovation. It provides an overview of the need for organizations to constantly change and adapt to their external environment in order to survive. It also discusses how Capita Symonds can help organizations transform their strategies, processes, behaviors, infrastructure, and customer service to create smarter and more sustainable operations. The document then goes into more detail on various aspects of organizational transformation.
This document provides background information on a student assignment analyzing foreign direct investment in Kazakhstan. The assignment includes an introduction outlining its structure, research objectives, and a literature review discussing an article on benefits of FDI in developing countries. It then provides definitions and discussions of FDI, including advantages and disadvantages. The main body is a case study on FDI opportunities in Kazakhstan, covering its geography, history, political system, economy and business environment.
Implementing innovation and commercialisation - Stuart Abbott, Zoë Prytherch ...HEA_AH
This presentation is linked to a workshop presented at the HEA Enhancement event ‘Successful students: enhancing employability through enterprise education’. The blog post that accompanies this presentation can be accessed via http://bit.ly/1JIE3wh
The document discusses entrepreneurship and the challenges of developing new technologies, referring to the example of Rimon Therapeutics. It describes Rimon's focus on developing novel polymer-based medical devices called "Theramers" for applications like wound healing. The document outlines Rimon's business strategy, pipeline of Theramer products in development, clinical trial results, and upcoming milestones.
Rm panel at translational rm forum (washington dc; april 6 8, 2011)v.1ProteusVenturePartners
The document discusses the formation of an international coalition called the Regenerative Medicine Coalition (RMC) comprising regenerative medicine translation centers. The goal of the RMC is to accelerate commercialization of regenerative medicine technologies by enabling more capital efficient development, facilitating collaborative projects, and reducing costs and time involved in early stage clinical development through shared resources and advances in platform technologies across member centers.
Bridging The Valley Of Death A Tale Of Two Culturesrwmalonemd
This document discusses the challenges of transitioning biotechnology discoveries from research to commercial products, known as crossing the "valley of death". It notes that on average only 1 in 4 to 1 in 5 biotechnology products in development achieve approval due to fundamental differences between the cultures of research and product development. Bridging this gap requires addressing regulatory, capital, and project management challenges throughout the product development process. The future of biotechnology will rely on rigorous project planning, outsourcing, earlier consideration of development pathways, and continual engagement between research and development teams.
This document discusses the evolution of quality management practices from a focus on cost savings through outsourcing to an increased emphasis on quality and risk mitigation. Two industry leaders believe this represents an opportunity for companies to improve quality systems and management. They see investments in quality as reducing costs in the long run. Better quality processes within complex supply chains are needed to ensure control over outsourced production. Risk mitigation strategies and sustainability practices can further strengthen quality programs. Companies may look to consultants and software to help mitigate risks in outsourced manufacturing and shared supply chains.
The document discusses strategies for developing biosimilars in a cost-effective manner. It notes that while the biopharmaceutical opportunity is large, biosimilar development faces significant challenges related to regulation, manufacturing complexity, and marketing limitations. Companies therefore pursue various strategies like building internal capabilities, outsourcing non-core functions, partnering, and acquisitions. The document uses Reliance Life Sciences as a case study, outlining its multi-pronged approach to developing an integrated biosimilars pipeline and capabilities through both internal investment and external partnerships and deals.
UL Product Mindset Industry Report Household ChemicalsUL
The document summarizes key findings from a study on the household chemicals industry. It finds that:
1) Manufacturers are confident in their product safety and innovation but less so in sustainability. Rising costs are their biggest supply chain challenge.
2) Product reliability impacts manufacturers' ability to compete currently, while innovation will be most important in the future.
3) Manufacturers see themselves as responsible for product safety and communicating it to consumers.
4) Consumers find product safety and performance most important when evaluating household chemicals and have concerns about long term exposure and skin irritation.
5) It is difficult for consumers to find product safety information about household chemicals.
This document summarizes an upcoming conference on pre-filled syringes in Europe. The two-day conference will feature presentations and discussions on pre-filled syringe formulations, filling and finishing processes, primary and secondary packaging developments, regulatory compliance, and patient safety approaches. It will also include two post-conference workshops on self-injection devices and safety issues within pre-filled syringes. Key industry leaders and experts will speak on topics such as biologics formulations, extractables and leachables, facility design strategies, and regulatory trends. The conference aims to explore challenges and solutions for pre-filled syringe development and commercialization.
This document provides an agenda for the "2nd Prefilled Syringes Americas" conference taking place from April 5-7, 2011 in the USA. The conference will discuss trends in pre-filled syringes including new materials, components, and processes. Key topics include plastic syringe systems, drug delivery devices, technological developments, and advanced formulations for biologics. Speakers will represent companies like Bristol-Myers Squibb, Gerresheimer, West Pharmaceutical, and Arecor. The event aims to explore industry requirements and the latest innovations in pre-filled syringe product development.
7th Cold Chain Distribution for PharmaceuticalsAbby Lombardi
This document provides information about the 7th Annual Cold Chain Distribution for Pharmaceuticals conference taking place from September 21-24, 2009 in Philadelphia, Pennsylvania. The conference will focus on partnerships, transportation processes, risk mitigation and temperature-controlled shipment of pharmaceutical products and supplies. Topics will include re-evaluating transportation and logistics strategies, ensuring regulatory compliance, establishing qualified shipping lanes and processes, and implementing effective "last mile" logistics. The conference will feature speakers from various pharmaceutical and logistics companies and government agencies. Pre-conference discussion forums and conference tracks will address issues such as cold chain program management, new refrigeration technologies, biological materials and clinical supplies shipping, and clinical logistics.
Will Biosimilars Be A Driver For InnovationAjaz Hussain
The Biosimilar debate touches upon several important reasons for innovation failure in a regulated environment – successful, scientific, resolution will be important for the entire sector.
The document discusses using a tobacco-based manufacturing platform for rapidly and cost-effectively producing vaccines and therapeutics. It outlines the business model, which involves licensing the technology to larger biotech companies, and describes initial customer feedback indicating the flu vaccine market may be difficult to enter but the therapeutics market, such as for alpha-1 antitrypsin, could be more promising. Prototyping efforts involve further characterizing alpha-1 antitrypsin production in tobacco plants.
This document discusses brand development and new product development (NPD). It begins with an introduction of the presenter, David G. Elliott, including his background in health and beauty marketing. The document then discusses how NPD involves both art and science. It provides examples of how to strategically develop brands through understanding consumer and shopper research, motivations, and retail needs. The summary emphasizes that successful NPD requires a strategic approach considering both the artistic and scientific elements of creating new products that meet consumer and retailer expectations.
The CDDI approach provides drug development services through a virtual asset development model using an external team of experienced professionals. This allows clients to outsource drug development functions and access dedicated experts in a flexible manner. By using CDDI's virtual teams, clients can reduce costs and infrastructure while expediting development timelines.
This report is a complement to a global study, Navigating the Product Mindset, that features marketplace trends, statistical data, differing stakeholders, varied geographies, diverse industries and a technical panel of UL experts. This report presents the key findings related to the food industry. It is based on 2,430 quantitative interviews with manufacturers and consumers across a range of significant export and import markets — China, Germany, India and the United States.
Navigating the Product Mindset and its additional industry reports seek to better understand market forces; drivers of decisions; findings related to safety, performance, sustainability and innovation; and the motivations behind these views.
The MIT Consortium on Adventitious Agent Contamination in Biomanufacturing aims to identify best practices for preventing contamination of biomanufacturing processes. The Consortium will provide a collaborative environment for member companies to share experiences and develop solutions. Initial projects include collecting and analyzing industry virus contamination data in a confidential manner to determine risk factors and mitigation strategies. The goal is to advance practices for ensuring product safety and quality.
This report is a complement to a global study, Navigating the Product Mindset, that features marketplace trends, statistical data, differing stakeholders, varied geographies, diverse industries and a technical panel of UL experts. This report presents the key findings related to the high-tech industry. It is based on 2,430 quantitative interviews with manufacturers and consumers across a range of significant export and import markets — China, Germany, India and the United States.
Navigating the Product Mindset and its additional industry reports seek to better understand market forces; drivers of decisions; findings related to safety, performance, sustainability and innovation; and the motivations behind these views.
This document presents a generic modular framework for implementing innovation and commercialization-oriented curricula through scenario-based and experiential learning. The framework is adaptable and scalable, covering topics like opportunity recognition, intellectual property, finance, and business strategy. Assessment includes feasibility reports, presentations, research tasks, and reflective logs.
The School of Bioscience applies this framework through student "company teams" that invent marketable biotech products addressing global issues. External speakers provide discipline-relevant content, and weekly plans guide students through a scenario culminating in a feasibility report and company pitch. Feedback indicates the innovative methodology develops students' commercial awareness and employability skills.
Slides from the CEDIM Innovation Series presentation. Includes a new business model framework, the business model as strategy cube and a design thinking oriented approach to business model innovation. @cedim
This document discusses business transformation and innovation. It provides an overview of the need for organizations to constantly change and adapt to their external environment in order to survive. It also discusses how Capita Symonds can help organizations transform their strategies, processes, behaviors, infrastructure, and customer service to create smarter and more sustainable operations. The document then goes into more detail on various aspects of organizational transformation.
This document provides background information on a student assignment analyzing foreign direct investment in Kazakhstan. The assignment includes an introduction outlining its structure, research objectives, and a literature review discussing an article on benefits of FDI in developing countries. It then provides definitions and discussions of FDI, including advantages and disadvantages. The main body is a case study on FDI opportunities in Kazakhstan, covering its geography, history, political system, economy and business environment.
Implementing innovation and commercialisation - Stuart Abbott, Zoë Prytherch ...HEA_AH
This presentation is linked to a workshop presented at the HEA Enhancement event ‘Successful students: enhancing employability through enterprise education’. The blog post that accompanies this presentation can be accessed via http://bit.ly/1JIE3wh
The document discusses entrepreneurship and the challenges of developing new technologies, referring to the example of Rimon Therapeutics. It describes Rimon's focus on developing novel polymer-based medical devices called "Theramers" for applications like wound healing. The document outlines Rimon's business strategy, pipeline of Theramer products in development, clinical trial results, and upcoming milestones.
Rm panel at translational rm forum (washington dc; april 6 8, 2011)v.1ProteusVenturePartners
The document discusses the formation of an international coalition called the Regenerative Medicine Coalition (RMC) comprising regenerative medicine translation centers. The goal of the RMC is to accelerate commercialization of regenerative medicine technologies by enabling more capital efficient development, facilitating collaborative projects, and reducing costs and time involved in early stage clinical development through shared resources and advances in platform technologies across member centers.
Bridging The Valley Of Death A Tale Of Two Culturesrwmalonemd
This document discusses the challenges of transitioning biotechnology discoveries from research to commercial products, known as crossing the "valley of death". It notes that on average only 1 in 4 to 1 in 5 biotechnology products in development achieve approval due to fundamental differences between the cultures of research and product development. Bridging this gap requires addressing regulatory, capital, and project management challenges throughout the product development process. The future of biotechnology will rely on rigorous project planning, outsourcing, earlier consideration of development pathways, and continual engagement between research and development teams.
This document discusses the evolution of quality management practices from a focus on cost savings through outsourcing to an increased emphasis on quality and risk mitigation. Two industry leaders believe this represents an opportunity for companies to improve quality systems and management. They see investments in quality as reducing costs in the long run. Better quality processes within complex supply chains are needed to ensure control over outsourced production. Risk mitigation strategies and sustainability practices can further strengthen quality programs. Companies may look to consultants and software to help mitigate risks in outsourced manufacturing and shared supply chains.
The document discusses strategies for developing biosimilars in a cost-effective manner. It notes that while the biopharmaceutical opportunity is large, biosimilar development faces significant challenges related to regulation, manufacturing complexity, and marketing limitations. Companies therefore pursue various strategies like building internal capabilities, outsourcing non-core functions, partnering, and acquisitions. The document uses Reliance Life Sciences as a case study, outlining its multi-pronged approach to developing an integrated biosimilars pipeline and capabilities through both internal investment and external partnerships and deals.
This document summarizes Microbix's annual general meeting for 2012. Key points include exiting 2012 as cash flow positive by closing a Kinlytic agreement, funding LumiSort development, relocating the VIRUSMAX joint venture, and growing virology profits. It also provides financial projections showing Kinlytic generating $100 million in revenue by year 3 and $400 million by year 5, and an overall gross sales target of $240 million across business segments by 2016.
This document outlines a business plan for producing therapeutic proteins like vaccines and alpha-1 antitrypsin using tobacco plants. It discusses using tobacco's manufacturing capabilities to rapidly and cost-effectively produce proteins. Target markets include seasonal flu vaccines, pandemic flu vaccines, and alpha-1 antitrypsin for treating deficiencies. The plan involves outsourcing manufacturing activities and establishing partnerships with larger biotech companies and government organizations. Financial metrics like costs, pricing, and capital requirements are considered to evaluate feasibility and profitability.
Sweet Sensors describes small, inexpensive diagnostic devices that can detect a variety of biological markers through quantitative tests adapted to many targets, including recreational drugs, heavy metals, toxins, bacteria, viruses, pharmaceuticals, and environmental and food safety hazards. The devices are described as having small form factors and being able to detect targets through adaptable tests in a quantitative manner.
Kennametal's innovation journey focused on strategic alignment, disciplined processes, and executive involvement. They created an Innovation Ventures Group to target emerging business opportunities beyond their core offerings. Their approach balances managing the core business while incubating new opportunities earlier in the innovation cycle through a portfolio of projects with varying levels of risk and market adjacency. Executive support was crucial for providing resources and governance over the innovation pipeline and portfolio.
Team Inserogen is developing a technology using tobacco plants as biofactories to produce therapeutics like vaccines and alpha-1 antitrypsin (AAT) more cost effectively and at large scale. Their technology could provide a reliable supply of recombinant AAT at lower cost than current treatments derived from human blood plasma. They are seeking funding and partnerships with biotech companies to advance their technology for producing AAT to treat AAT deficiency, a genetic condition affecting lung health.
This document provides information about an upcoming conference on single-use bioreactors being held in London on November 1-2, 2012. The conference will feature speakers from pharmaceutical and biotech companies as well as equipment suppliers discussing topics such as using single-use bioreactors to increase flexibility, reduce costs and speed up research and development. Attendees will learn about case studies on scaling up production with disposable technology and accelerating cell culture development. The conference offers sponsorship and exhibition opportunities for companies to promote their services and products.
Robert Kirschbaum (DSM) - The balancing act between radical and incremental i...Anis Bedda
Robert Kirschbaum (DSM)
Title: The balancing act between radical and incremental innovation (and the role of intrapreneurs)
Intrapreneurship Conference 2014
www.intrapreneurshipconference.com
#Intracnf14
Our technology platform has potential market opportunities in producing therapeutics like vaccines. We are testing the hypothesis that our platform can be scaled up and commercialized cost-effectively. We spoke with experts in vaccine manufacturing, distribution, commercialization of biotech platforms, and more. They validated pain points in current vaccine production and interest in faster, more scalable platforms. Next steps are understanding customer relationships and decision-making to establish a commercialization strategy and business model. We will continue engaging experts and customers.
The document discusses product development and management tools used by businesses. It covers product life cycles, portfolio management matrices like the BCG Matrix and GE Matrix, and the product development process. Key decisions for product managers include which products to introduce, keep, promote, and delete or continue at different stages of the product life cycle. Developing products that satisfy customer needs and have a competitive advantage is important for business success.
The document discusses Thermo Scientific's leadership in serving science through analytical instruments, equipment, reagents, software and services. It highlights the company's size and scale, unmatched capabilities, portfolio of leading brands, and mission to make the world healthier, cleaner and safer. Key strengths include global industry leadership, ability to continuously invest in growth opportunities through R&D, and an excellent track record of financial performance. New products are presented for applications such as sample preparation, analysis, and data interpretation.
The document discusses Thermo Scientific's leadership in serving science through analytical instruments, equipment, reagents, software and services. It highlights the company's size and scale, unmatched capabilities, portfolio of leading brands, and mission to make the world healthier, cleaner and safer. Key strengths include global industry leadership, ability to continuously invest in growth opportunities through R&D, and an excellent track record of financial performance. New products are presented for applications such as sample preparation, analysis, and data interpretation.
The document discusses Thermo Scientific's leadership in serving science through analytical instruments, equipment, reagents, software and services. It highlights the company's size and scale, unmatched capabilities, portfolio of leading brands, and mission to make the world healthier, cleaner and safer. Key strengths include global industry leadership, ability to continuously invest in growth opportunities through R&D, and an excellent track record of financial performance. New products are presented for applications including sample preparation, sample analysis, and data interpretation.
The document discusses Thermo Scientific's leadership in serving science through analytical instruments, equipment, reagents, software and services. It highlights the company's size and scale, unmatched capabilities, portfolio of leading brands, and mission to make the world healthier, cleaner and safer. Key strengths include global industry leadership, ability to continuously invest in growth opportunities through R&D, and an excellent track record of financial performance. New products are presented for applications like sample preparation, analysis and data interpretation.
BCG Overview Of Services And Value Propositions 2010chalverson
Biologics Consulting Group (BCG) is a regulatory consulting firm that has over 17 years of experience helping life sciences companies navigate the regulatory process to bring new technologies and products to market. BCG offers comprehensive regulatory strategic planning and consulting services across multiple industries and major global markets. Their team of experts, which includes both former FDA reviewers and individuals with industry experience, can provide guidance on all stages of product development from pre-clinical research through FDA approval and commercialization.
Similar to Ws from innovation to commercialisation marcel van der sluis (20)
This company was founded in 2005 and develops a non-random platform technology for biological crop improvements. They have a pipeline of biostimulants and biopesticides that have shown consistent yield improvements. They are raising a Series B round of €10M to support the commercial launch of their first products by 2018.
This document outlines the business innovation strategy of Sensoterra. It plans to use the best possible technology to measure everything and monetize data through value-based pricing. Sensoterra aims to lead the sector by designing sensors with adequate technology focused only on soil moisture. It will provide data for free with the lowest possible pricing through an aggressive rollout. The goal is to build a team of sector leaders and reach 100,000 sensors by 2020. Sensoterra works with supply chain and technology partners and uses moisture sensors and autonomous pilots on the best available data.
Epibreed has developed a technique called TEgenesis to accelerate natural evolution in crops for rapid breeding of stress tolerance and production of inducible traits. TEgenesis works by subjecting crops to stress conditions which triggers a controlled burst of transposable element activity that introduces genetic and epigenetic diversity. This allows for fast, directed and natural crop breeding without transgenic techniques. Epibreed's current services involve applying TEgenesis to customers' crops to identify genes responsible for traits of interest and establish exclusive usage agreements based on service fees and royalties.
The document discusses the evolution of supply chain management from the 1960s to present day. It traces the development from a focus on inventory management and cost control to integrated systems involving purchasing, manufacturing, and order management. Modern supply chains aim to create an optimized value network with real-time decision support across a collaborative extended network. The document then discusses the traditional horticultural supply chain and outlines its characteristics and results, including high risks and waste. It suggests most potential for value creation is in breeding and selling crops. Future supply chains will require growers, auctions, and traders to redefine their value propositions.
This document summarizes trends in the global floriculture industry from 2005 to 2016 and discusses challenges and opportunities going forward. Key points include:
- Global floriculture exports recovered after the recession but volatility remains. Production is shifting to equatorial countries with lower costs.
- The UK and US markets grew strongly but the picture in Europe is diverse. The Russian market boomed then declined sharply.
- Online sales are rising rapidly while traditional wholesalers face pressure. Supply chains will likely consolidate into breeding, production, and retail.
- Sustainability, technology, data exchange, and flexibility will be important for players to address uncertainty and diverse country growth patterns.
Felda Global Ventures is a leading global agribusiness company and the world's largest producer of crude palm oil. It has a diverse portfolio including palm upstream and downstream operations, trading and logistics, rubber, and sugar. The company's R&D and breeding program develops high-yielding and disease-resistant oil palm varieties like DxP Felda 3 Way through conventional and marker-assisted selection. Field trials show higher yields from higher density planting of the new varieties. The integrated approach combining breeding, biotechnology and genomics aims to produce sustainable palm oil through high-performing planting materials.
This document discusses the development of a novel crop called Flexilis, which is a species of dandelion that can produce natural rubber. It provides an overview of the challenges in developing a new crop from initial roadmapping through commercialization. It then describes Flexilis as an alternative source of natural rubber that can be grown in temperate regions. The document outlines the molecular breeding research that has been done to increase the rubber yield of Flexilis from an initial 200 kg/ha to a target yield of 750 kg/ha through several generations of breeding and selection.
Evogene presented an overview of their company and technology. They are a leading biotechnology company that uses predictive biology to develop products for improved crop productivity. Their technology platform integrates large datasets to identify genetic elements, chemical compounds, and microbes. These outputs form the basis for developing improved seeds, innovative agrochemicals, and novel agrobiologicals. Evogene has multiple product programs and strategic collaborations with major agriculture companies. Their business model focuses on licensing agreements that generate revenue from R&D payments, milestones, and royalties on product sales.
3b. Biotechnolgies & Genomics - Jane TheakerIventus
LGC provides workflow solutions to address challenges in agricultural biotechnology. They developed customized tools and protocols to help with sample collection, DNA extraction, SNP discovery and validation, and bioinformatics analysis. This improves throughput, reduces costs, and helps customers breed crops faster and more efficiently. LGC's bespoke solutions and global services and support help customers overcome challenges and gain competitive advantages.
3a. Robotics, big data & precision agro - Robert BerendesIventus
This document discusses digital disruption in the agriculture and food industry. It begins by outlining the context of digital disruption and its implications for the industry. Several examples of digital disruptors are then provided, including companies using technologies like sensors, drones, AI and data analytics to increase farming efficiency and reduce costs across the agricultural value chain. The document concludes by noting that digitization will impact all business functions and the largest effects may be felt beyond the farm, such as in new business systems that emerge across the industry.
3a. Robotics, big data & precision agro - Peter MaesIventus
Koppert Biological Systems is a global leader in biocontrol founded in 1967 in response to issues with chemical pesticides. Starting with beneficial mites, Koppert now takes a holistic biological approach across horticulture and agriculture. Trends like sustainable intensification, food safety, and precision agriculture are increasing demand for residue-free biological solutions. Koppert is developing new technologies like UAVs, sensors, and software to remotely monitor crops and precisely release beneficial organisms as part of smart farming systems. This integration of biological knowledge with digital tools and autonomous applications aims to help farmers produce more with fewer inputs and less environmental impact.
Bayer Crop Science is uniquely positioned to deliver next generation agricultural products through innovation in vegetable seeds. They are accelerating discovery through computational life sciences, targeted genome optimization, and experimentation. This includes integration and analysis of data from diverse sources, computer models to supplement lab tests, and targeted optimization of crop genomes. Bayer fosters innovation in vegetable seeds through urban farming enabled by modern technologies, capitalizing on global expertise through grants, and providing access to breakthrough technologies at their Life Science Center.
1) SESVanderHave is a sugar beet seed producer focused on improving sugar beet efficiency through research and breeding.
2) Over 25 years, sugar beet productivity has doubled due to improvements in genetics, agronomy, disease control, and factory processing.
3) One opportunity to further increase competitiveness is reducing transport costs, which represent over 13% of total beet production costs. Decreasing the moisture content of sugar beets by 30% could save the EU sugar industry 150 million Euros annually in transport costs.
This document discusses broomrape, a devastating sunflower weed, and strategies for its sustainable management. It notes that broomrape has expanded significantly in European sunflower fields over the past few decades and now threatens over 50% of acreage. The document advocates an integrated approach combining genetic resistance, selective herbicides, and good agricultural practices. It provides examples of integrated solutions successfully used in other crops and argues this is most effective for long-term control as broomrape evolves new races. The sustainable management of pests like broomrape is important for securing the global sunflower oil supply chain.
1b. insights and understanding breakthrough r&d - Els BeirnaertIventus
VIB's protein aggregation technology can be used for crop protection and improvement applications. It allows targeted knockdown of proteins through induced protein-protein aggregation. This can be used to target pest and disease organism proteins for crop protection, or plant proteins to enhance traits. The technology is protected by patents and can be deployed through transgenic crops or as peptide treatments. Proof of concept has been shown for applications in agriculture, bacterial infections, and cancer.
1a. Realizing new solutions ip & regulatory - René CustersIventus
1) The document discusses whether genome edited crops fall under the EU's GMO legislation.
2) It analyzes the key definitions and criteria in the EU legislation, including the difference between a genetically modified organism and an organism subject to GMO regulation.
3) There are arguments that genome editing that results in combinations of genetic material that can occur naturally does not meet the definition of a GMO, and is therefore not subject to GMO regulation. However, the final determination can only be made by the European Court of Justice.
1a. Realizing new solutions ip & regulatory - Franck CoutandIventus
This document discusses the patentability of breeding processes and products derived from such processes under European law. It summarizes key decisions and statements from the European Patent Office, European Parliament, European Commission, and European Union Council regarding whether plants or plant materials produced by essentially biological processes can be patented. Recent developments suggest the European Patent Office may change its practice to exclude patenting such products in line with European Union guidance, though legal certainty will require a new ruling from the Enlarged Board of Appeals.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
ABDOMINAL TRAUMA in pediatrics part one.drhasanrajab
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Ws from innovation to commercialisation marcel van der sluis
1. Drug Development Cluster
Drug Development Cluster
“An Integrated Outsourcing Network”
An Integrated Outsourcing Network
“From Innovation to Commercialization”
Confidential
www.drugdevelopmentcluster.com
2. This Workshop
“Outsourcing” = “Out‐License”
Hilde Windels – SepsPharma Marc de Weer – Galapagos
Cost Reduction Needs to get to clinic
Risk control
Ri k l Selection of contractors
S l i f
Faster to Market Project Management
Pharmaco economics Efficiency
Confidential
www.drugdevelopmentcluster.com
3. New Outsourcing Model
g
“Smarter commercialization by integrated innovation ”
Serve virtual R&D
Reduce cost
Reduce Time to Market
Reduce risk
Confidential
www.drugdevelopmentcluster.com
4. Productivity and Team Integration
y g
65.5%
65 5%
89.7%
New Product Development, Robert G Cooper
Confidential
www.drugdevelopmentcluster.com
5. Where is Pharma R&D taking place
gp
Medicinal cGMP Drug Safety Salt Screening Drug Product
Chemistry Manufacturing Evaluation Polymorphism Development
Contract Labs
Contract Labs
Universities Pharma R&D
Biotechs Hospitals
Confidential
www.drugdevelopmentcluster.com
6. Functional Walls in Drug Development
g p
Statement: “Drug development R&D is a fragmented process”
• Big Company R&D is poorly integrated – too BIG to manage
• Also independent service provider work in isolation
Also independent service provider work in isolation
• Where are the autonomous, cross functional teams necessary for
productive product development ?
Medicinal cGMP Drug Product
Chemistry Manufacturing Development
Confidential
www.drugdevelopmentcluster.com
7. Large Pharma Melt‐Down
Increased R&D expenditure… …Reduced output
30% 60
25% 50
20% 40
R&D as % of sales
15%
1 % 30
10% 20
5% 10
0% 0
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004* 2005* 2006* 2007* 2008* 2009*
• More complex scientific targets • Inefficient innovation
• Increased regulatory cost to avoid risk • Waste of time and money
Restructuring of Large Pharma R&D
Cost Reduction – Bi t h are Innovators
C t R d ti Biotechs I t
Confidential
www.drugdevelopmentcluster.com
8. Restructuring R&D | 1. Cost Reduction
• R&D sites closed, moved, or sold to CROs
Examples: Covance‐Sanofi Aventis, Aptuit‐GSK
• Portfolio maintenance by Acquisitions
Organon‐MSD, Solvay‐Abbott, buy small biotechs
• Large Pharma are reducing R&D cost by skipping the early development work
Step in after POC
p
Save 7 years of R&D
Confidential
www.drugdevelopmentcluster.com
9. Biotech: The New Innovator
• In‐licensing, co‐development, risk sharing
• Biotechs are filling the innovation gap
• Biotech focus: Out license after POC (Phase II)
Biotech focus: Out‐license after POC (Phase II)
Confidential
www.drugdevelopmentcluster.com
10. Changing world for contractors
• Limited resources within Biotechs – virtual operation
• Outsource full set of services from screening to the clinic
Outsource full set of services from screening to the clinic
• Focus on cost reduction and reduced time to market
• CROs are consulting ‐ Drug Development Black‐Box
Knowledge Flows
Biotech
Large Pharma
CRO
CRO
Old Situation
Old Situation New Situation
New Situation
Confidential
www.drugdevelopmentcluster.com
11. Opportunity for new outsourcing model
pp y g
• Virtual Biotechs are the innovators
• Consultative role for CRO ‐
Consultative role for CRO Opportunity
• R&D must get cost effective and more efficient
• Broader sets of work are outsourced – Opportunity
Drug Development Cluster :
D D l t Cl t
• Offers broad set of services – “one stop multi shop”
• Offers knowledge to get to POC
g g
• Integration saves R&D cost and time
• Make life easier for virtual pharma
• Integrated multiple CROs a paradox ? How does it work ?
Integrated multiple CROs a paradox ? How does it work ?
References R&D Mash‐ups. Pharmaceutical Technology Europe, September 2010
A Problem Shared. Worldpharma vol 2, 2010
Lean Sigma in R&D. Drug Discovery Today, June 2009
Confidential
www.drugdevelopmentcluster.com
12. Outsourcing to multiple CROs
Core Process
Medicinal cGMP Drug Safety Salt Screening Drug Product
Chemistry Manufacturing Evaluation Polymorphism Development
Support Process
S tP
Acquisition Acquisition Acquisition Acquisition Acquisition
Technical discussion Technical discussion Technical discussion Technical discussion Technical discussion
Legal aspects Legal aspects Legal aspects Legal aspects Legal aspects
Shipping of samples
Shi i f l Shipping of samples
Shi i f l Shipping of samples
Shi i f l Shipping of samples
Shi i f l Shipping of samples
Shi i f l
Project Management Project Management Project Management Project Management Project Management
Project Updates Project Updates Project Updates Project Updates Project Updates
Reporting Reporting Reporting Reporting Reporting
• Slioed non‐integrated process
• Many overlapping activities
Confidential
www.drugdevelopmentcluster.com
13. Outsourcing to the Drug Development Cluster
Core Process
Medicinal cGMP Drug Safety Salt Screening Drug Product
Chemistry Manufacturing Evaluation Polymorphism Development
Shared Support Process
pp
Acquisition
Technical discussion
Legal aspects
Shipping of samples
Project Management
j
• Faster process Project Updates
• Reduce wasting money Reporting
Confidential
www.drugdevelopmentcluster.com
14. Lean Sigma | Eight points of waste
g | g p
Over production
Knowledge 1 Waiting
8 2
7 3
Movements
6 4 Shipping
5
Stock
Rework Over optimisation
Stock
Confidential
15. Non value added activities | Project Startup
| j p
Reduction of waste by combined activities
Quantification of value streams
Finding CRO
Acquisition
Acquisition
Site visits Startup activities
CDA Exchange
Reduce with 64%
Kick offs
Audits
A dit
Proposals
Confidential
www.drugdevelopmentcluster.com
16. Quantification of Value Streams | Execution
Analytical development
A l i ld l
Safety assessments
Shipping of samples
Lab reproduction
p During project execution
Technology transfer Reduce with 49%
Project discussions
Knowledge transfer
Overall saving after reducing
non value added activities:
non‐value added activities:
76 days = € 80,000
Confidential
www.drugdevelopmentcluster.com
17. How does it work
• Project team tailor made for customer
• Managed by dedicated project manager
• l ibl d bli i
Flexible and no obligations
• Working with the cluster is an option
• No extra money involved
• Saves money
Saves money
Confidential
www.drugdevelopmentcluster.com
18. Parallel Development
Medicinal Chemistry Mercachem
Candidate Nomin
Route Scouting Mercachem
Clinic/IMPD
Drug Safety Studies NOTOX NOTOX
Salt Screening & Polymorphism Avantium
Process Development Cambridge Major
D
nation
GMP Manufacturing Cambridge Major
Drug Product Development SEPS Pharma
Better project flow
Knowledge build‐up
Avoid over‐delivery
Flag pit‐falls in early phase of project
Confidential
www.drugdevelopmentcluster.com
20. Finalized Projects
Based on approx 10 projects for biotech companies
Lead Optimization – Solid State Chem – GMP Manufacturing
Library Synthesis – D
Lib S th i Drug Safety Evaluation
S f t E l ti
GMP Manufacturing – Solid State Chem ‐ Drug Product Development
Saved up to 12 months of development time
Saved up to 12 months of development time
Confidential
www.drugdevelopmentcluster.com